AMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 157.1%, free cash flow fell 351.4% and total debt rose 8.22%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow AMRX
AMNEAL PHARMACEUTICALS, INC. (AMRX) Altman Z-score
AMNEAL PHARMACEUTICALS, INC.'s Altman Z-score for fiscal 2025 is 1.94, in the grey zone (1.81–2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.94 | 0.58 |
| FY2024 | 1.35 | 0.30 |
| FY2023 | 1.06 | 0.45 |
| FY2022 | 0.61 | (0.33) |
| FY2021 | 0.94 | 0.09 |
| FY2020 | 0.84 | 0.44 |
| FY2019 | 0.41 | (0.45) |
| FY2018 | 0.86 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.28 | — | 0.34 | |
| Retained earnings / total assets | (0.15) | — | −0.20 | |
| EBIT / total assets | 0.11 | — | 0.35 | |
| Market value of equity / total liabilities | 1.05 | — | 0.63 | |
| Sales / total assets | 0.82 | — | 0.82 | |
| Altman Z-score | Grey zone | 1.94 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 2.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 10.4× |
| ALKS Alkermes plc compare | 5.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.3× |
| LNTH Lantheus Holdings, Inc. compare | 4.3× |
| HIMS Hims & Hers Health, Inc. compare | 4.1× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.3× |
| AMRX AMNEAL PHARMACEUTICALS, INC. | 1.9× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −2.9× |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets